Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
about
Fungal allergy in asthma-state of the art and research needsUS Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisPharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Current ciprofloxacin usage in children hospitalized in a referral hospital in ParisOne Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation.Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosisLiposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.Clinical pharmacokinetics of inhaled antimicrobials.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Ciprofloxacin Use in Hospitalized Children: Approved or Off-label?
P2860
Q22001138-E30D38A7-5EE4-4474-BD86-114F1D9E90D7Q26775974-4EE6E22B-5857-475A-AE1E-D48DDB5FEEB6Q34297656-2D654B0E-9427-479B-945C-A425124F732FQ34741643-9AFE67E9-0048-4941-9EE4-58B412180BA7Q37094805-1B764AC0-2BEF-4F37-BFC0-B7EC356753BDQ38101836-C55E62AC-FC4B-4F75-B89F-6A33A0564973Q38133781-4AC901B4-DDD5-40DD-895F-4874645BA6E6Q38170953-731ADC3E-60C3-4923-9D47-2349D6EF26ADQ38214155-90B0BAEA-8DF1-48BF-939F-F100E2B1FD7FQ38270626-854F77CC-3981-4735-B4A9-604126D69800Q38367260-D36D1905-B2CF-47D6-BABE-00B50A7463DCQ38369608-B9736CDC-37B7-469B-AC72-8C418C6509BFQ49237658-A4B1D2E1-345B-4FD7-A2A3-EE93428BDD00
P2860
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimization of anti-pseudomon ...... ations: III. fluoroquinolones.
@en
type
label
Optimization of anti-pseudomon ...... ations: III. fluoroquinolones.
@en
prefLabel
Optimization of anti-pseudomon ...... ations: III. fluoroquinolones.
@en
P2093
P2860
P356
P1476
Optimization of anti-pseudomon ...... ations: III. fluoroquinolones.
@en
P2093
C Dustin Waters
Catherine M T Sherwin
Chris Stockmann
David C Young
Jeffery T Zobell
Krow Ampofo
Michael G Spigarelli
P2860
P304
P356
10.1002/PPUL.22667
P577
2012-09-04T00:00:00Z